Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 17/20 | 0.67 |
| ▸ | MMP9 | P14780 | 15/20 | 0.67 |
| ▸ | MMP12 | P39900 | 12/20 | 0.67 |
| ▸ | MMP2 | P08253 | 12/20 | 0.67 |
| ▸ | MMP14 | P50281 | 11/20 | 0.67 |
| ▸ | MMP15 | P51511 | 11/20 | 0.67 |
| ▸ | MMP16 | P51512 | 11/20 | 0.67 |
| ▸ | MMP26 | Q9NRE1 | 10/20 | 0.67 |
| ▸ | MMP7 | P09237 | 10/20 | 0.67 |
| ▸ | MMP3 | P08254 | 5/20 | 0.47 |
| ▸ | MMP13 | P45452 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022069 | 0.93 | MMP1 (0.57) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL3534955 | 0.92 | MMP1 (0.55) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL1023198 | 0.91 | MMP1 (0.56) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL1024080 | 0.87 | MMP1 (0.53) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL3536039 | 0.85 | MMP1 (0.67) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL3532212 | 0.85 | MMP1 (0.48) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL1020994 | 0.85 | MMP1 (0.50) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL1023199 | 0.84 | MMP1 (0.51) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL1021988 | 0.83 | MMP1 (0.63) | MMP1MMP9MMP12MMP2MMP14 | |
| SCHEMBL1021053 | 0.83 | MMP1 (0.47) | MMP1MMP9MMP12MMP2MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858619-B2 | Substituted tetrahydroisochinolines as MMP inhibitors, related production method and use as medicine | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858619-B2 | Substituted tetrahydroisochinolines as MMP inhibitors, related production method and use as medicine | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858619-B2 | Substituted tetrahydroisochinolines as MMP inhibitors, related production method and use as medicine | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | MMP9, MMP3, MMP2 | MMP1 9/4885MMP9 1/4885MMP12 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.